Skip to content
value.today
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc.

Total raised
$88 M
1 round on record
Latest round
$88 M
Feb 2020
First round on record
Feb 2020
Today
Went public
See the company page

Spruce Biosciences, Inc. is listed today as Spruce Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Spruce Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$50 MPrivate placement after listing$50 to $250 million

Spruce Biosciences, Inc.: Private sale, Oct 2025

Investors in this round

21 investors had bought by the notice of Oct 17, 2025: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Spruce Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Equity offering includes common stock and pre-funded warrants to purchase common stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$3,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Javier Szwarcberg · Executive Officer, Director
  • Michael Grey · Executive Officer, Director
  • Samir Gharib · Executive Officer
  • Bali Muralidhar · Director
  • Daniel Spiegelman · Director
  • Kirk Ways · Director
  • Percival Barretto-Ko · Director
  • Simpson Camilla · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Citizens JMP Securities, LLC (CRD 22208) · San Francisco, CaliforniaSold in all US states
  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in all US states
  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Remarks in the notice

  • On the use of proceeds: “The Company shall use the net proceeds of the sale of the Securities hereunder for non-clinical and clinical development activities for its product candidate, pre-commercial activities and general corporate purposes.”

Signed by Samir Gharib, President & CFO. Source: SEC Form D, newest notice filed Oct 17, 2025. Read the notice at the SEC.

equity, optionsSEC
Feb 2023$54 MPrivate placement after listing$50 to $250 million

Spruce Biosciences, Inc.: Private sale, Feb 2023

Investors in this round

20 investors had bought by the notice of Feb 28, 2023: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Spruce Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$54 M of $54 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Equity offering includes common stock, warrants to purchase common stock and pre-funded warrants to purchase common stock.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$2,437,603
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Javier Szwarcberg · Executive Officer, Director
  • Michael Grey · Executive Officer, Director
  • Ralph William Charlton III · Executive Officer
  • Samir Gharib · Executive Officer
  • Bali Muralidhar · Director
  • Daniel Spiegelman · Director
  • Dina Chaya · Director
  • Kirk Ways · Director
  • Simpson Camilla · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SVB Securities LLC (CRD 39011) · Boston, MassachusettsSold in CA, IL, MA, MD, MO, NY, PA, and outside the US

Remarks in the notice

  • On the use of proceeds: “The Company shall use the net proceeds of the sale of the securities for non-clinical and clinical development activities for its product candidate, pre-commercial activities and general corporate purposes.”

Signed by Samir Gharib, President & CFO. Source: SEC Form D, newest notice filed Feb 28, 2023. Read the notice at the SEC.

equity, optionsSEC
Feb 2020$88 MNo. 1$50 to $250 million

Spruce Biosciences, Inc.: Raise no. 1, Feb 2020

Investors in this round

11 investors had bought by the notice of Aug 14, 2020: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Spruce Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$88 M of $88 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
not stated
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard King · Executive Officer, Director
  • Samir Gharib · Executive Officer
  • Bali Muralidhar · Director
  • Camilla Simpson · Director
  • Dina Chaya · Director
  • Jonas Hansson · Director
  • Michael Grey · Director
  • Niall O'Donnell · Director
  • Tiba Aynechi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard King, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 14, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Spruce Biosciences, Inc. had no revenue when it filed its newest notice of a funding round (Oct 2025).

    SEC Form D (revenue range) · Oct 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2025

Products and services#

No products or services of Spruce Biosciences, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Spruce Biosciences, Inc.
InvestorKindAmountRoundRoleSource
HealthCap VIII, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Omega Fund VI GP, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Omega Fund VI GP Manager, Ltd.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Omega Fund VI, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
RiverVest Venture Fund III, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
RiverVest Venture Fund III (Ohio), L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
RiverVest Venture Fund IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.

Largest shareholders today

Institutions holding Spruce Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Spruce Biosciences, Inc.
NameRoleNamed in
Javier SzwarcbergExecutive officerOct 2025
Michael GreyExecutive officerOct 2025
Samir GharibExecutive officerOct 2025
Ralph William Charlton IIIExecutive officerFeb 2023
Richard KingExecutive officerAug 2020
Bali MuralidharDirectorOct 2025
Daniel SpiegelmanDirectorOct 2025
Javier SzwarcbergDirectorOct 2025
Kirk WaysDirectorOct 2025
Michael GreyDirectorOct 2025
Percival Barretto-KoDirectorOct 2025
Simpson CamillaDirectorOct 2025
Tiba AynechiDirectorOct 2025
Dina ChayaDirectorFeb 2023
Camilla SimpsonDirectorAug 2020
Jonas HanssonDirectorAug 2020
Niall O'DonnellDirectorAug 2020
Richard KingDirectorAug 2020

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.